Eli Lilly is hoping new data from its Taltz (ixekizumab ... Novartis’ Cosentyx has already been approved in this use on the basis of a 16-week study which measured the proportion of patients ...
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback